Canal Insurance Company’s Vertex Pharmaceuticals VRTX Stock Holding History

Canal Insurance Company’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-40,000	Closed	-$948K	–	87
2017 Q2	$948K	Buy	40,000 +39,600	+9,900%	+$4.77M	0.35%	61
2017 Q1	$450K	Buy	+400	New	+$35.2K	0.16%	67
2015 Q2	–	Sell	-8,800	Closed	-$63K	–	91
2015 Q1	$63K	Sell	8,800 -8,300	-49%	-$994K	0.02%	81
2014 Q4	$199K	Buy	+17,100	New	+$1.93M	0.07%	80
2014 Q3	–	Sell	-10,000	Closed	-$100K	–	108
2014 Q2	$100K	Buy	+10,000	New	+$701K	0.03%	90

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Canal Insurance Company's VRTX Position: Q3 2017 in Review

Canal Insurance Company sold out of Vertex Pharmaceuticals (VRTX) in Q3 2017, closing a stake of 40,000 shares — an estimated $5.16M sold.

Canal Insurance Company first reported a position in VRTX in Q2 2013 and held it in 14 quarters. The position peaked at $5.16M in Q2 2017. 611 funds tracked by Wall St. Rank hold VRTX as of Q3 2017.

Canal Insurance Company reported no remaining Vertex Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
Canal Insurance Company sold 40,000 Vertex Pharmaceuticals shares in Q3 2017, an estimated $5.16M.
Canal Insurance Company first reported a position in Vertex Pharmaceuticals in Q2 2013 and held it in 14 quarters.
Canal Insurance Company's Vertex Pharmaceuticals position peaked at $5.16M in Q2 2017.
611 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2017.

Based on Canal Insurance Company's 13F filing for Q3 2017, filed 13 Nov 2017.